Buhl R, Banerji D. Int J Chron Obstruct Pulmon Dis. 2012;7:729–741.
On page 737 in the first paragraph of the “Safety” section, the final sentence “Serious adverse events occurred with a slightly lower frequency in the glycopyrronium treatment group (11%) compared with placebo (13%) and the tiotropium group (15%, ).32,33” should read “Serious adverse events occurred with a slightly lower frequency in the glycopyrronium treatment group (10%) compared with placebo (13%) and the tiotropium group (15%, ).32,33”
Table 3 Most frequent adverse events (≥5% in any treatment group); SAEs occurring in ≥5 patients in any treatment group, deaths, discontinuations due to adverse events and electrocardiographic abnormalities; pooled data from GLOW1 and GLOW2. Adapted from D’Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011;12:15632 and Kerwin E, Hébert J, Korenblat P, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: The GLOW2 study. Eur Respir J. July 26, 2012.33
On page 737 in the second paragraph of the “Safety” section, the first sentence “Discontinuations due to adverse events were 10% in the placebo group and 8% in the glycopyrronium and tiotropium groups.” should read “Discontinuations due to adverse events were 9% in the placebo group and 7% in the glycopyrronium and tiotropium groups.”
On page 737, contains incorrect information. The corrected Table is set out below.